No echo features of ACP were found, with no significant difference between RV systolic function, pulmonary acceleration time and pulmonary velocity time integral between survivors and nonsurvivors.
Additionally, intra-operative variables (cardio pulmonary bypass time, aortic cross clamp time, nephro-toxins and utilization of cardioplegia, intra-aortic balloon pumps, blood products, and vaso-active medications) were also collected.
Attenuation-time graph corresponding to the regions of interest (b) shows prolonged pulmonary circulation time of 16 s in this patient due to aortic stenosis (normal pulmonary transit time is approximately 7 9 s).
Prolonged pulmonary circulation time in a patient with aortic stenosis.
The likely explanation for these findings can be increased pulmonary transit time.
Recently, a clinical trial with acetazolamide, in patients with CMS has proven to be effective in increasing mean pulmonary acceleration time and decreasing pulmonary vascular resistance index, which might be indirectly due the reduction of hematocrit.
Mean pulmonary acceleration time (ms) is significantly lower in CMS subjects than in SL and HA natives, and pulmonary vascular resistance index (Wood units) is higher in CMS and HA natives when compared with SL dwellers.
However, the chitosan-modified PLGA nanocomposite particles designed by Agglomaster™ exhibited superior properties to those obtained by Mechanofusion™ with respect to the redispersibility of fine particles in aqueous liquid, the pulmonary retention time and pharmacological effects.
CECT demonstrates excellent opacification of the right heart, but poor opacification in the left heart related to prolonged pulmonary circulation time in a patient with left ventricular systolic dysfunction.
